Lonza

Next week, our Cell & Gene leaders will travel to the Alliance for Regenerative Medicine’s Meeting on the MESA and play an active role focused on accelerating the successful commercialization of Cell & Gene Therapies globally. If you are attending, don't miss the panel discussion on "Investing in Cell and Gene Therapy – Current Global Market Trends", joined by Thomas Fellner, our Vice President, Global Head of Operations for Cell & Gene Technologies. We’d welcome the opportunity to sit down with you and discuss bringing your science to market. Please reach out to us using the Partnering App or through our website (https://lnkd.in/eMYDVTmU) to meet with one of our team on-site. #RealizingPotentialTogether #commercialization #GeneTherapy #CellTherapy

One of the most important goals of genetic engineering, especially within the biopharmaceutical industry space, is the ability to produce therapeutic proteins. Over the years spent working in this field, Pichia pastoris has become my personal favorite expression system, mainly due to its versatility across scales and the appropriate folding and secretion of recombinant proteins expressed in this system, and their ease of purification. Lonza has developed the XS® Pichia Expression System to help accommodate industry trends, eliminate production bottlenecks, align downstream processing, and drive breakthroughs into the clinic. Learn more about P. pastoris and its use at Lonza in my new blog.  #PichiaPastoris #Recombinant #Lonza #PharmaceuticalIndustry #RandDBlog

Today, we completed our acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California (US) from Roche for USD 1.2 billion. With a total bioreactor capacity of around 330,000 liters, the Vacaville facility significantly extends our mammalian manufacturing footprint in the US, the world’s largest pharmaceutical market. We extend a warm welcome to our new colleagues in Vacaville as the site joins our global Biologics manufacturing network. #AHealthierWorld #Acquisition #Growth #Biologics

👉 Check out our incredible lineup of speakers at Festival of Biologics by swiping through the graphics in this post. In addition, our team will be on-site to talk with you about all things biologics.   Full session info:   🔷 “Innovative Approaches in Cell Line Development: Leveraging Technology and Case Studies for Scalable Process Optimization” Tuesday, October 15th, 16:50-17:10 Alejandro Infante, Senior Technologist, Cell Culture Development Full session abstract: https://lnkd.in/eEVzcSUf 🔷“From Lab to Large-Scale Process Validation: Mastering Regulatory Compliance” Tuesday, October 15th, 17:30 Evelyn Sollner, Project Manager, Purification Development  Full session abstract: https://lnkd.in/eB8TaJy6   🔷"Enhanced Vector Technology for Improved Expression Control of Bispecific Antibodies" Tuesday, October 15th, 17:30 Peter O'Callaghan, Senior Director, Licensing Full session abstract: https://lnkd.in/eKA5kmry   🔷“Efficient Development Processes for Biologics” Thursday, 17 October, 9:00 Christoph Grapentin, PhD, Group Leader Formulation Development #LonzaBio #ThePeoplePoweringBiologics

There is only one week to go till CPHI 2024 in Milan. Our team is getting ready for the biggest tradeshow of the year and is excited to meet F2F with customers and peers in the industry. Pass by the Lonza booth #6A2, enjoy a cup of coffee from our barista and learn more about Lonza’s latest innovations and offerings. #CPHI2024 #CPHIMilan 

Biologics In Focus - the new edition is ready for you to read. Stay ahead of the curve in the biologics industry with our September edition of "Biologics In Focus". This month’s edition gives you insights about: - Accelerating Drug Development: discover how our innovative DNA-to-IND programs can streamline your biologics journey. - Manufacturing Excellence: learn about our expanded microbial manufacturing capabilities and how they're addressing growing industry demands. - Technological Advancements: explore the latest breakthroughs in GS-CHO technology and its transformative impact on biopharmaceutical production. - Industry Insights: get the latest on industry trends, CDMO rankings, and Lonza's expansion. - Customer Success: a real customer case study from Pionyr Immunotherapeutics about their successful partnership. Don't miss out! Subscribe to our newsletter today. #LonzaBio #Pharma  #Biotechnology  #thePeoplePoweringBiologics

Today we announced the extension of our collaboration with Acumen to to enable the potential future commercial launch of sabirnetug (ACU193). Acumen is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta (Aβ) oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Sabirnetug is the first humanized monoclonal antibody to clinically demonstrate selective target engagement of AβOs in AD patients. The extended collaboration builds upon an existing successful relationship in which we provide drug substance manufacturing for the Phase 2 clinical supply of sabirnetug. Read more about our extended collaboration here: https://lnkd.in/dtWUP3uY #AHealthierWorld #PharmaceuticalManufacturing #DrugProduct #Alzheimers

Join us for an insightful webinar which will explore recent developments that highlight the ability to adapt an automated manufacturing platform to different processes, such as positively or negatively selecting T cells directly from apheresis. Our experts Tamara Laskowski and Nuala Trainor will share insights on successful automation of a CAR-T process with minimal operator intervention. Register now to secure your spot: https://lnkd.in/dubtuySA #CARTtherapy #celltherapy #genetherapy #LonzaCGT

Today marks nine years since UN member states adopted the Sustainable Development Goals (SDGs), which defined a path to build a more sustainable world by 2030. At Lonza, we identified seven of those goals where we could make a meaningful difference to the communities we live and work in. At Lonza, we remain fully committed to the goals and working together to solve these global challenges. Our seven SDGs contribute to our societal value and help inform our long-term strategy and decision making. 💊 Good health and well-being: Delivering innovative medicines that help to save, extend and enhance lives. 📚 Quality Education: Fostering collaboration with the scientific community and nurturing the development of our employees. ⚖ Gender Equality: Supporting a diverse global employee community and promoting increased representation of women in leadership. 💧 Clean water and sanitation: Actively managing the impact of water usage on communities and the environment. 🔬 Industry, innovation and infrastructure: Investing in innovation and sustainable growth projects. 🚛 Responsible consumption and production: Working towards a more responsible supply chain and limiting material consumption and waste generation. 🌍 Climate action: Continually reducing energy, greenhouse gas emissions and material demand. #TogetherForTheSDGs #AMeaningfulDifference #SDG #Sustainability

We have just signed a long-term commercial supply agreement for CASGEVY® with Vertex Pharmaceuticals.   CASGEVY® is the first cell therapy based on the CRISPR/Cas9 technology, discoverers of which were awarded the Nobel Prize in Chemistry in 2020.   Under the terms of the agreement, Vertex will leverage our scientific, regulatory and manufacturing expertise, global manufacturing network, and first-hand experience in the commercial manufacture of cell therapy products. We will manufacture CASGEVY® at our cGMP cell therapy manufacturing facilities in Geleen (NL), with plans to expand to our Portsmouth (US) facility.   Daniel Palmacci, President of Cell & Gene at Lonza, commented: “It is a privilege to work with Vertex on bringing its innovative and cutting-edge medicines to patients suffering from life-threatening diseases. We are also pleased to reach a significant milestone towards supporting the commercial manufacture of CASGEVY® by receiving the regulatory approval at our state-of-the-art cell therapy manufacturing site in Geleen.” Read more here: https://lnkd.in/g4tkriM3 #AHealthierWorld #CellTherapy #PharmaceuticalManufacturing #Biotech #Pharma